))
ART Doesn’t Increase Hormone Receptor-Positive Breast Cancer Recurrence Risk
Manage episode 388173608 series 3525104
Content provided by Breastcancer.org. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Breastcancer.org or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
At the 2023 San Antonio Breast Cancer Symposium, Dr. Hatem Azim presented a new analysis of information from the POSITIVE trial, which found that younger women diagnosed with early-stage, hormone receptor-positive breast cancer could safely pause hormonal therapy to try to become pregnant. His new analysis looked at whether the women could use fertility preservation and assisted reproductive technologies (ART) without increasing the risk of the cancer coming back (recurrence).
Listen to the podcast to hear Dr. Azim discuss:
- the types of fertility preservation and ART used
- which techniques were the most successful
- the results of his analysis
303 episodes
Share
